John Jezorwski

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

Joseph J. Eron, Chloe Orkin, Joel E. Gallant et al. · AIDS · 2018 · 85 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials

Sophia Gailhardou, Anna Skipetrova, Gustavo H. Dayan et al. · PLoS neglected tropical diseases · 2016 · 52 citations · Full text

Veterinary Medicine, Infectious Diseases, Hypersensitivity +16

JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2

Kosh Agarwal, Florian van Bömmel, Pietro Lampertico et al. · Journal of Hepatology · 2024 · 47 citations · Full text

Pharmacy, Molecular Biology, Pharmacotherapy +14

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Joseph J. Eron, Chloe Orkin, Douglas Cunningham et al. · Antiviral Research · 2019 · 36 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

Chloe Orkin, Joseph J. Eron, Jürgen K. Rockstroh et al. · AIDS · 2019 · 36 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17